secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001654954-24-014016
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%
--------------------------------------------------------------------------------

- Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.
- Diagnostics segment revenue $0.5M (+38% YoY); Therapeutic Device $6.5M (+9%).
- Net loss $6.7M vs $0.5M loss a year ago (prior year included $2.2M acquisition gain).
- Adjusted non-GAAP EBITDA loss $4.3M; operating cash burn ~$5.2M, adjusted $4.0M.
- Cash & securities $77.8M at Sept 30, down from $83.0M at June 30; no guidance change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424014016/0001654954-24-014016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424014016/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer